Our Radiotherapy Results in Patients with Primary Non-Small Cell Lung Cancer with Brain Metastases
Abstract
Objective: Lung cancer is the most common cancer worldwide and is among the leading causes of cancer death. The aim of this study is to examine the survival of patients who received radiotherapy for the brain metastases, whose primary is non-small cell lung cancer, and also determine the factors that are like to affect the survival and to examine the results of radiotherapy in these patients as well.
Materials and Methods: This study included 99 patients with primary non-small cell lung cancer. All patients with brain metastases received radiotherapy. The patients were grouped and compared according to the number of brain metastases, whether surgery was performed for brain metastasis, gender, pathology and stage of the primary focus, visceral organ involvement, and ECOG performance status after brain metastasis developed.
Results: The change in survival rate according to the number of brain metastases at the time of diagnosis was found statistically significant (p<0.01). When the stages and survival of the patients at the time of diagnosis were compared, it was statistically significant (p<0.01). Similarly, the differences among the ECOG/PS status was also statistically significant (p<0.01). When patients with visceral organ metastases were divided into two groups as to groups as dead and alive, it was observed that the number of exitus that most of the patients were lost to their metastatic state (p<0.001).
Conclusion: Age, gender, the number of brain metastases the number of brain metastases brain metastasis, surgery, ECOG/PS, chemotherapy, radiotherapy and visceral organ metastasis were found to be factors affecting survival in patients with brain metastases.
Keywords
Kaynakça
- Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, et al. SEER Cancer Statistics Review, 1975-2011, National Cancer Institute. Bethesda, MD, https://seer.cancer.gov/archive/csr/1975_2011/
- Hellman S, Weichselbaum RR. Oligometastases. J Clin Oncol. 1995;13:8–10.
- Plönes T, Dango S, Brugger W, Ludwig C, Stoelben E. Potentially curative surgical therapy in oligometastatic nonsmall cell lung cancer. Dtsch Med Wochenschr. 2014;139(11):538–542.
- Ashworth A, Rodrigues G, Boldt G, Palma D. Is there an oligometastatic state in non-small cell lung cancer? A systematic review of the literature. Lung Cancer. 2013;82:197–203.
- Barnholtz-Sloan JS, Sloan AE, Davis FG, Vigneau FD, Lai P, Sawaya RE. Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System. J Clin Oncol. 2004;22:2865–2872.
- Welsh JW, Komaki R, Amini A, Munsell MF, Unger W, Allen PK et al. Phase II trial of erlotinib plus concurrent whole-brain radiation therapy for patients with brain metastases from non-small-cell lung cancer. J Clin Oncol. 2013;31:895–902.
- Davey P, Hoegler D, Ennis M, Smith J. A phase III study of accelerated versus conventional hypofractionated whole brain irradiation in patients of good performance status with brain metastases not suitable for surgical excision. Radiother Oncol. 2008;88:173–176.
- Grossi F, Kubota K, Cappuzzo F, d Mrinis F, Gridelli C, Aita M et al. Future scenarios for the treatment of advanced non-small cell lung cancer: Focus on taxane-containing regimens. Oncologist. 2010;15:1102–1112.
- Sundstrom JT, Minn H, Lertola KK, Nordman E. Prognosis of patients treated for intracranial metastase with whole-brain irradiation. Ann Med. 1998;30:296-299.
- Gaspar L, Scott C, Rotman M, Asbell S, Phillips T, Wasserman T et al. Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys. 1997;37:745-754.